睿知中国医院研究地图
候选清单

正在招募肺癌I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

ClinicalTrials.gov 上登记的一项肺癌开放试验,由四川大学华西医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)四川大学华西医院West China Hospital成都医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06348797,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. Patients with recurrent or refractory small cell lung cancer (SCLC) confirmed by histology or cytology who have relapsed or progressed after treatment with one previous platinum-based regimen;

    入选标准第 1 条

  3. Patients in limited-stage at the initial diagnosis must undergo radical thoracic radiotherapy and the time of tumor progression is not less than 1 months from the end of radiotherapy, or radical thoracic dose radiotherapy cannot be performed for specific reasons; The time elapsed since the completion of radiotherapy for brain metastases shall be no less than 1 months;

    入选标准第 7 条

  4. At least one extracranial measurable lesion (RECIST v1.1) exists;for lesion after radiotherapy, must be confirmed that the lesion has progressed ;

    入选标准第 6 条

    Received major surgical procedures (except for diagnosis) within 4 weeks before PBMCs collection, or are expected to require major surgical procedures during the study;

    排除标准第 2 条

    Previous treatment with DLL 3 target drugs or CAR-T or other gene-modified T cells;

    排除标准第 10 条

    Received any other Investigational drug within 28 days prior to PBMCs collection;

    排除标准第 11 条

  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;

    入选标准第 4 条

  6. Poorly controlled or symptomatic hypercalcemia (ionic calcium> 1.5 mmol/L, calcium> 12 mg/dL or corrected calcium> ULN);

    排除标准第 6 条

  7. Female patients or male reproductive age patients and their partners should agree to effective contraception from sighing Informed Consent Form (ICF) to 6 months after the last BHP01 infusion.

    入选标准第 9 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;试验排除的其他疾病。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06348797,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Patients with recurrent or refractory small cell lung cancer (SCLC) confirmed by histology or cytology who have relapsed or progressed after treatment with one previous platinum-based regimen;
  2. Patients can provide sufficient tumor tissue (fresh or paraffin sections, etc.);
  3. Age 18 \~70 (including boundary), for both men and women;
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
  5. Life expectancy ≥3 months;
  6. At least one extracranial measurable lesion (RECIST v1.1) exists;for lesion after radiotherapy, must be confirmed that the lesion has progressed ;
  7. Patients in limited-stage at the initial diagnosis must undergo radical thoracic radiotherapy and the time of tumor progression is not less than 1 months from the end of radiotherapy, or radical thoracic dose radiotherapy cannot be performed for specific reasons; The time elapsed since the completion of radiotherapy for brain metastases shall be no less than 1 months;
  8. The test results of human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis C and syphilis were negative at screening (If hepatitis B core antibody (HBcAb) is positive, additional HBV DNA testing is required, and subjects whose test result is less than the reference value can be included in the study) ;
  9. Female patients or male reproductive age patients and their partners should agree to effective contraception from sighing Informed Consent Form (ICF) to 6 months after the last BHP01 infusion.

排除标准:Exclusion Criteria:

  1. Patients with known primary Central Nervous System (CNS) tumor, or meningeal metastasis, or patients with unstable CNS metastasis (symptomatic, requiring hormonal therapy within 4 weeks before investigational treatment, or no radiographic evidence of stabilization of the lesion for more than 4 weeks);
  2. Received major surgical procedures (except for diagnosis) within 4 weeks before PBMCs collection, or are expected to require major surgical procedures during the study;
  3. Received Chinese herbal medicine or Chinese patent medicine for anti-tumor indications within 7 days before Peripheral Blood Mononuclear Cells (PBMCs) collection;
  4. Patients with a history of idiopathic pulmonary fibrosis, mechanical pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia or idiopathic pneumonia, or evidence of active pneumonia by chest computer tomography (CT) at screening [a history of radiation pneumonia (fibrosis) in the irradiated field may participate in this study];
  5. Poorly controlled pleural effusion, pericardial effusion, or ascites requiring repeated drainage procedures (once a month or more frequently);
  6. Poorly controlled or symptomatic hypercalcemia (ionic calcium> 1.5 mmol/L, calcium> 12 mg/dL or corrected calcium> ULN);
  7. Presence of active or previous autoimmune diseases or immunodeficiencies, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, etc.;
  8. Severe infection within 4 weeks before the start of PBMCs collection, including but not limited to hospitalization due to infection, bacteremia, severe pneumonia, or any active infection that may affect the patient's safety;
  9. Serious cardiovascular and cerebrovascular diseases (such as heart disease ≥New York Heart Association class II, myocardial infarction or cerebrovascular accident), unstable arrhythmia or unstable angina pectoris within 3 months before PBMCs collection;
  10. Previous treatment with DLL 3 target drugs or CAR-T or other gene-modified T cells;
  11. Received any other Investigational drug within 28 days prior to PBMCs collection;
  12. A history of mental illness;
  13. Incapacitated persons or persons with limited capacity;
  14. pregnant or lactating females; Males or females who are unwilling to use adequate contraception; Females of childbearing potential are required to undergo a pregnancy study during the screening period;

引自 ClinicalTrials.gov, NCT06348797, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06348797,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06348797